These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34837061)

  • 21. Synthesis and Preclinical Evaluation of TPA-Based Zinc Chelators as Metallo-β-lactamase Inhibitors.
    Schnaars C; Kildahl-Andersen G; Prandina A; Popal R; Radix S; Le Borgne M; Gjøen T; Andresen AMS; Heikal A; Økstad OA; Fröhlich C; Samuelsen Ø; Lauksund S; Jordheim LP; Rongved P; Åstrand OAH
    ACS Infect Dis; 2018 Sep; 4(9):1407-1422. PubMed ID: 30022668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sulfamoyl Heteroarylcarboxylic Acids as Promising Metallo-β-Lactamase Inhibitors for Controlling Bacterial Carbapenem Resistance.
    Wachino JI; Jin W; Kimura K; Kurosaki H; Sato A; Arakawa Y
    mBio; 2020 Mar; 11(2):. PubMed ID: 32184250
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-based discovery of LpxC inhibitors.
    Zhang J; Chan A; Lippa B; Cross JB; Liu C; Yin N; Romero JA; Lawrence J; Heney R; Herradura P; Goss J; Clark C; Abel C; Zhang Y; Poutsiaka KM; Epie F; Conrad M; Mahamoon A; Nguyen K; Chavan A; Clark E; Li TC; Cheng RK; Wood M; Andersen OA; Brooks M; Kwong J; Barker J; Parr IB; Gu Y; Ryan MD; Coleman S; Metcalf CA
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1670-1680. PubMed ID: 28302397
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure- and Ligand-Dynamics-Based Design of Novel Antibiotics Targeting Lipid A Enzymes LpxC and LpxH in Gram-Negative Bacteria.
    Zhou P; Hong J
    Acc Chem Res; 2021 Apr; 54(7):1623-1634. PubMed ID: 33720682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of specific inhibitors on metallo-β-carbapenemases detected in Escherichia coli and Klebsiella pneumoniae isolates.
    Abbas HA; Kadry AA; Shaker GH; Goda RM
    Microb Pathog; 2019 Jul; 132():266-274. PubMed ID: 31096002
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is meropenem MIC increase against KPC-producing Klebsiella pneumoniae correlated with increased resistance rates against other antimicrobials with Gram-negative activity?
    Cojutti P; Sartor A; Bassetti M; Scarparo C; Pea F
    J Glob Antimicrob Resist; 2018 Sep; 14():238-241. PubMed ID: 29775786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preclinical safety and efficacy characterization of an LpxC inhibitor against Gram-negative pathogens.
    Zhao J; Cochrane CS; Najeeb J; Gooden D; Sciandra C; Fan P; Lemaitre N; Newns K; Nicholas RA; Guan Z; Thaden JT; Fowler VG; Spasojevic I; Sebbane F; Toone EJ; Duncan C; Gammans R; Zhou P
    Sci Transl Med; 2023 Aug; 15(708):eadf5668. PubMed ID: 37556556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. N-Hydroxyformamide LpxC inhibitors, their in vivo efficacy in a mouse Escherichia coli infection model, and their safety in a rat hemodynamic assay.
    Furuya T; Shapiro AB; Comita-Prevoir J; Kuenstner EJ; Zhang J; Ribe SD; Chen A; Hines D; Moussa SH; Carter NM; Sylvester MA; Romero JAC; Vega CV; Sacco MD; Chen Y; O'Donnell JP; Durand-Reville TF; Miller AA; Tommasi RA
    Bioorg Med Chem; 2020 Dec; 28(24):115826. PubMed ID: 33160146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
    Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
    Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Klebsiella pneumoniae carbapenemase (KPC) in urinary infection isolates.
    Bedenić B; Sardelić S; Bogdanić M; Zarfel G; Beader N; Šuto S; Krilanović M; Vraneš J
    Arch Microbiol; 2021 May; 203(4):1825-1831. PubMed ID: 33507339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effects of carbapenems on bacterial load and host immune response in a Klebsiella pneumoniae murine pneumonia model.
    Hilliard JJ; Melton JL; Hall L; Abbanat D; Fernandez J; Ward CK; Bunting RA; Barron A; Lynch AS; Flamm RK
    Antimicrob Agents Chemother; 2011 Feb; 55(2):836-44. PubMed ID: 21135187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small molecule LpxC inhibitors against gram-negative bacteria: Advances and future perspectives.
    Niu Z; Lei P; Wang Y; Wang J; Yang J; Zhang J
    Eur J Med Chem; 2023 May; 253():115326. PubMed ID: 37023679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Water molecule-mediated selective inhibition of bacterial zinc metalloproteinases by non-hydroxamate compounds: Ab initio molecular simulations.
    Saito R; Imai K; Takimoto D; Ezawa T; Sugiyama S; Takimoto-Kamimura M; Kurita N
    J Mol Graph Model; 2022 Jul; 114():108200. PubMed ID: 35453045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Site-directed mutagenesis of the bacterial metalloamidase UDP-(3-O-acyl)-N-acetylglucosamine deacetylase (LpxC). Identification of the zinc binding site.
    Jackman JE; Raetz CR; Fierke CA
    Biochemistry; 2001 Jan; 40(2):514-23. PubMed ID: 11148046
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antibacterial Properties of Tebipenem Pivoxil Tablet, a New Oral Carbapenem Preparation against a Variety of Pathogenic Bacteria in Vitro and in Vivo.
    Yao Q; Wang J; Cui T; Yang Z; Su M; Zhao P; Yan H; Zhan Y; Yang H
    Molecules; 2016 Jan; 21(1):62. PubMed ID: 26751436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bicyclomycin Activity against Multidrug-Resistant Gram-Negative Pathogens.
    Wang W; Zhu X; Luo H; Wang Z; Hong A; Zeng J; Li L; Wang D; Deng X; Zhao X
    Microbiol Spectr; 2023 Feb; 11(1):e0379022. PubMed ID: 36533939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Study of
    Zhang W; Guo Y; Yang Y; Dong D; Zheng Y; Zhu D; Hu F
    Microb Drug Resist; 2020 Mar; 26(3):204-210. PubMed ID: 31553260
    [No Abstract]   [Full Text] [Related]  

  • 39. Vancomycin Analogue Restores Meropenem Activity against NDM-1 Gram-Negative Pathogens.
    Yarlagadda V; Sarkar P; Samaddar S; Manjunath GB; Mitra SD; Paramanandham K; Shome BR; Haldar J
    ACS Infect Dis; 2018 Jul; 4(7):1093-1101. PubMed ID: 29726673
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The inhibitory and binding studies of methyl-sulfone hydroxamate based inhibitors against LpxC from drug resistant Moraxella catarrhalis using biophysical, biochemical and in silico approaches.
    Sharma A; Kumar V; Pratap S; Kumar P
    Int J Biol Macromol; 2018 Oct; 118(Pt B):1747-1762. PubMed ID: 30017978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.